The $6 Billion Miss: Ionis Pharmaceuticals Tumbles 20% as Wainua's Heart Trial Fails
Ionis Pharmaceuticals sank as much as 21% Thursday after Wainua failed a pivotal Phase 3 heart trial, erasing the market's biggest bet on its pipeline. Partner AstraZeneca fell alongside it, while rival Alnylam surged on reduced competition.